![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company will develop its proprietary single shot, thermostabilization vaccine technology (ALTA™) and will study the ALTA™ mechanism of action using model antigens, such as those targeting HIV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2023
Details:
The funding will be used to apply VitriVax’s ALTA™ platform to the lead B. pseudomallei vaccine candidate, which is currently a three-dose regimen, with the goal of developing a single injection, thermostable vaccine formulation to protect against melioidosis and glanders.
Lead Product(s): Thermostable Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Defense Threat Reduction Agency
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 19, 2023